


Atty. Dkt. No. P65315US0
Serial No.: 09/509,559

Favorable action is requested.

Respectfully submitted,

JACOBSON·HOLMAN PLLC

By:


William E. Player
Reg. No. 31,409

400 Seventh Street, N.W.
The Jenifer Building
Washington, D.C. 20004
Tel.: (202) 638-6666
Atty. Dkt. No.: P65315US0
Date: April 26, 2002
R. HOME: rthomas 2002 April P65315amd.wpd

Marked Up versions of Amendments

Replace the paragraphs at page 2, line 4, through page 3, line 18, with the following:

Cadherin-1 human (28-154) [(SEQ ID NO: 1)]:

CHPGFDAESYTFTVPRRHLEGRVLGRVNFCTGRQRTAYFSLDTRFKVGTGCVITVKR-
PLRFHNPQIHFLVYAWDSTYRKFS TKVTLNGHHHRPPPHQASVSGIQAELLTFPNSSP-
GLRRQKR

Cadherin-2 human (24-159) [(SEQ ID NO: 2)]:

EASGEIALCKTGFPEDVYS AVL SKDVHEGQPLLNVFSNCNGKRKVQYESSEPADFKVD-
EDGMVYAVRSEPLSSEHAKFLIYAQDKETQEKWQKLSLKPTLTEESVKESAEVEEIVF-
PRQFSKHSGHLQRQKR

Cadherin-3 human (27-107) [(SEQ ID NO: 3)]:

CP,AVFREAEVTLEAGGAEEQEPGQALGKVFMGQEPALFSTDNDDFTVRNGETVQER-
RSLKERNPLKIFPSKRILRRHKR

Cadherin-4 human (21-169) [(SEQ ID NO: 4)]:

HNEDLTTRETCKAGFSEDDYTALISQNI LEGE KLLQVKSSCVG TKGTQYETNSMDFKG-
ADGTVFATRELQVPSEQVAFTVTAWDSQTA EKWD AVLVAQTSSPHSGHKPQKGKKVVA-
LDPSPPPKDTLLPWPQHQNANGLRRRKR

Cadherin-5 human (26-47) [(SEQ ID NO: 5)]:

AGANPAQRDTHSLLPTHRQKR

Cadherin-6 human (19-53) [(SEQ ID NO: 6)]:

TLSTPLSKRTSGEPAKKRALELSGNSKNELNRKR

Marked Up versions of Amendments

Cadherin-6 human (19-51) [(SEQ ID NO: 7)]:

TLSTPLSKRTSGFPAKKRALELSGNSKNELNRS

Cadherin-8 human [(SEQ ID NO: 8)]:

MLLDLWTPLIILWITLPPCIYMAPMNQSQVLMMSGPLELNSLGEEQRILNRSKR

Cadherin-B human (Cadherin-11) Precursor (23-53) [(SEQ ID NO: 9)]:

FAPERRGHLRPSFHGHHEKGKEGQVLQRSKR

Cadherin-B human (Cadherin-11) Precursor (26-51) [(SEQ ID NO: 10)]:

ERRGHLRPSFHGHHEKGKEGQVLQRS (OB-CDGF)

Cadherin-C human (Cadherin-12) -Brain-Cadherin Precursor (24- 54) [(SEQ ID NO: 11)]:

QPQPQQTALATEPRENVIIHLPQQRSHFQRVKR

Cadherin-C human (Cadherin-12) -Brain-Cadherin Precursor (24- 52) [(SEQ ID NO: 12)]:

QPQPQQTALATEPRENVIIHLPQQRSHFQRV

Cadherin-D human (Cadherin 13) (23-138) [(SEQ ID NO: 13)]:

EDLDCTPGFQQKVFHINQPAEFIEDQSILNLTFSDCKGNDKLRYEVSSPYFKVNSDGG-
LVALRNITAVGKTLFVHARTPHAEFDMAELVIVGGKDISLQDIFKFARTSPVPRQKRP-
SVLLLLSLFSLACL

Cadherin-F human (Cadherin 14) (22-60) [(SEQ ID NO: 14)]:

VPGWRRPTTLYPWRRAPALSRVRRRAWVIPISVSENHKKR. --

Replace the first paragraph at page 7 with the following:

Marked Up versions of Amendments

-- ERRGHLRPSFHGHHEKGKEGQVLQRS [(SEQ ID NO: 10)] --

Replace the paragraph at page 13, line 15, with the following:

ERRGHLRPSFHGHHEKGKEGQVLQRS [(SEQ ID NO: 10)] --

Replace the first complete paragraph at page 14 with the following:

-- Synthesis of the peptide having the sequence ERRGHLRPSFHGHHEKGKEGQVLQRS [(SEQ ID NO: 10)] was performed according to the Merrifield solid phase method starting from protected Fmoc amino acids. The synthetic peptide was purified by reversed-phase chromatography. The identity and purity of the substance were proven using mass spectrometry, sequence analysis and capillary zone electrophoresis. --

Replace the fourth complete paragraph at page 16 with the following:

-- The peptide corresponding to the CDGF region of cadherin-12 (BR-cadherin; N-cadherin-2) having the amino acid sequence QPQPQQLATEPRENVIHLPGQRSHFQRV [(SEQ ID NO: 12)], which has been synthesized by solid-phase synthesis as described under Example 1 for OB-CDGF, was tested for its survival-promoting effect on primary cultures of neurons from spinal ganglia of chicken embryos. --

Replace the fourth complete paragraph at page 17 with the following:

-- The peptide corresponding to the CDGF region of cadherin-6 having the amino acid sequence TLSTPLSKRTSGFPAKKRALELSGNSKNELNRS [(SEQ ID NO: 7)] which has been synthesized by solid-phase synthesis as described under Example for OB-CDGF, was tested for its survival-promoting effect on primary cultures of

Marked Up versions of Amendments

neurons from spinal ganglia of chicken embryos. The test model has the design as described in Example 2. --

Replace the first paragraph at page 7 with the following:

-- ERRGHLRPSFHGHHEKGKEGQVLQRS --

IN THE CLAIMS

Rewrite claim 4 as follows.

4 (amended). A CDGF having the sequence

Cadherin-1 human (28-154) [(SEQ ID NO: 1)]:

CHPGFDAESYTFTVPRRHLEGRVLGRVNFCTGRQRTAYFSLDTRFKVGTGCVITVKR-
PLRFHNPQIHFLVYAWDSTYRKFKSTKVTNLNGHHHRPPPHQASVSGIQAELLTFPNSSP-
GLRRQKR

Cadherin-2 human (24-159) [(SEQ ID NO: 2)]:

EASGEIALCKTGFPEDVYSVLSKDVHEGQPLLNVFSNCNGKRKVQYESSEPADFKVD-
EDGMVYAVRSEPLSSEHAKFLIYAQDKETQEKWQKLSLKPTLTEESVKESAEVEEIVF-
PRQFSKHSGHLQRQKR

Cadherin-3 human (27-107) [(SEQ ID NO: 3)]:

CP.AVFREA EVTLEAGGAEQEPGQALGKVFMGQEPALFSTDNDDFTVRNGETVQER-
RSLKERNPLKIFPSKRILRRHKR

Marked Up versions of Amendments

Cadherin-4 human (21-169) [(SEQ ID NO: 4)]:

HNEDLTTRETCKAGFSEDDYTALISQNILEGEKLLQVKSSCVGKTGTQYETNSMDFKG-
ADGTVFATRELQVPSEQVAFTVTAWDSQTAEKWDAVLVAQTSSPHSGHKPQKGKKVVA-
LDPSPPPKDTLLPWPQHQNANGLRRRKR

Cadherin-5 human (26-47) [(SEQ ID NO: 5)]:

AGANPAQRDTHSLLPTHRRQKR

Cadherin-6 human (19-53) [(SEQ ID NO: 6)]:

TLSTPLSKRTSGEPAKKRALELSGNSKNELNRSKR

Cadherin-6 human (19-51) [(SEQ ID NO: 7)]:

TLSTPLSKRTSGFPAKKRALELSGNSKNELNRS

Cadherin-8 human [(SEQ ID NO: 8)]:

MLLDLWTPILWITLPPCIYMAPMNQSQVLMMSGPLELNSLGEEQRILNRSKR

Cadherin-B human (Cadherin-11) Precursor (23-53) [(SEQ ID NO: 9)]:

FAPERRGHLRPSFHGHHEKGKEGQVLQRSKR

Cadherin-B human (Cadherin-11) Precursor (26-51) [(SEQ ID NO: 10)]:

ERRGHLRPSFHGHHEKGKEGQVLQRS (OB-CDGF)

Cadherin-C human (Cadherin-12) -Brain-Cadherin Precursor (24- 54) [(SEQ ID NO: 11)]:

QPQPQQTLATEPRENVIHLPQQRSHFQRVKR

Cadherin-C human (Cadherin-12) -Brain-Cadherin Precursor (24- 52) [(SEQ ID NO: 12)]:

Marked Up versions of Amendments

QPQPQQLATEPRENVHLPGQRSHFQRV

Cadherin-D human (Cadherin 13) (23-138) [(SEQ ID NO: 13)]:

EDLDCTPGFQQKVFHINQPAEFIEDQSILNLTFSACKGNDKLRYEVSPPYFKVNSDGG-
LVALRNITAVGKTLFVHARTPHAEFDMAELVIVGGKDISLQDIFKFARTSPVPRQKRP-
SVLLLSLFLACL

Cadherin-F human (Cadherin 14) (22-60) [(SEQ ID NO: 14)]:

VPGWRRPTTLYPWRRAPALSRVRRRAWVIPISVSENHKKR.